(Reuters) – Shares in AstraZeneca fell more than 4% on Wednesday after the publication of an abstract on its experimental precision drug’s use in lung cancer in a late-stage trial disappointed some analysts.
The abstract was published ahead the European Society for Medical Oncology’s (ESMO) congress that kicks off in Madrid on Friday.
By 1219 GMT, AstraZeneca shares were dwon 3.7% in London, while the broader STOXX Health Careindex was off 1%.
(This story has been refiled to fix a typo in paragraph 3)
(Reporting by Danilo Masoni and Maggie Fick)
